Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTB-NG6
- Development stage
- Phase 1
- Lead developer
- LimmaTech Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LTB-NG6 is a multivalent bioconjugate vaccine candidate developed by LimmaTech Biologics for the prevention of gonorrhea, an infection caused by the bacterium *Neisseria gonorrhoeae*. The vaccine utilizes LimmaTech's proprietary bioconjugation technology to link bacterial antigens to a carrier protein, aiming to elicit a robust and broad-spectrum immune response. This approach is intended to overcome the challenges posed by the high genetic variability and increasing antimicrobial resistance of *N. gonorrhoeae*. LTB-NG6 is currently being evaluated in a Phase 1 clinical trial (NCT06404450) to assess its safety, tolerability, and immunogenicity in healthy adults.
Beyond the preview
Go deeper on LTB-NG6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTB-NG6.